Salvianolic acid A prevents the pathological progression of hepatic fibrosis in high-fat diet-fed and streptozotocin-induced diabetic rats

American Journal of Chinese Medicine

Volumn 42, Issue 5, 2014, Pages 1183-1198

  Qiang, Guifen ^a   Yang, Xiuying ^a,b   Xuan, Qi ^c   Shi, Lili ^a   Zhang, Hengai ^a   Chen, Bainian ^a   Li, Xiaoxiu ^a   Zu, Mian ^a,b   Zhou, Dan ^a,b   Guo, Jing ^a,b   Yang, Haiguang ^a,b   Zhang, Li ^a,b   Du, Guanhua ^a,b  

^a INSTITUTE OF MATERIA MEDICA   (China)

^b Beijing Key Laboratory of Drug Target Identification and Drug Screening   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Hepatic Fibrosis; Salvianolic Acid A; TGF 1; Type 2 Diabetes; SMA

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ANTIDIABETIC AGENT; COLLAGEN TYPE 1; COLLAGEN TYPE 3; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLANT MEDICINAL PRODUCT; SALVIANOLIC ACID A; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; ACTIN; ALKENE; CAFFEIC ACID DERIVATIVE; LACTIC ACID DERIVATIVE; POLYPHENOL; SALVIANOLIC ACID; SMOOTH MUSCLE ACTIN, RAT; STREPTOZOCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIABETES CONTROL; DISEASE COURSE; DRUG MECHANISM; HYPERLIPIDEMIA; LIPID DIET; LIVER CELL; LIVER FIBROSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; RAT; RESPIRATORY FUNCTION; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; ADVERSE EFFECTS; ANIMAL; COMPLICATION; EXPERIMENTAL DIABETES MELLITUS; LIVER; LIVER CIRRHOSIS; METABOLISM; PATHOLOGY; PHYTOTHERAPY; SPRAGUE DAWLEY RAT;

ACTINS; ALKENES; ANIMALS; CAFFEIC ACIDS; DIABETES MELLITUS, EXPERIMENTAL; DIET, HIGH-FAT; DISEASE PROGRESSION; LACTATES; LIVER; LIVER CIRRHOSIS; PHYTOTHERAPY; POLYPHENOLS; RATS, SPRAGUE-DAWLEY; STREPTOZOCIN; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84926122689     PISSN: 0192415X     EISSN: 17936853     Source Type: Journal    
DOI: 10.1142/S0192415X14500748     Document Type: Article

References (36)

1. Annoni, G., F.R. Weiner and M.A. Zern. Increased transforming growth factor-beta 1 gene expression in human liver disease. J. Hepatol. 14: 259-264, 1992.
2. Berson, A., V. De Beco, P. Letteron, M.A. Robin, C. Moreau, J. El Kahwaji, N. Verthier, G. Feldmann, B. Fromenty and D. Pessayre. Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. Gastroenterology 114: 764-774, 1998.
3. Chance, B. and G.R. Williams. The respiratory chain and oxidative phosphorylation. Adv. Enzymol. Relat. Subj. Biochem. 17: 65-134, 1956
4. Chinese Society of Hepatology. Diagnostic criteria of nonalcoholic fatty liver disease. Chin. J. Hepatol. 11: 71-73, 2003.
5. Day, C.P. and O.F. James. Steatohepatitis: A tale of two "hits"? Gastroenterology 114: 842-845, 1998.
6. De Bleser, P.J., G. Xu, K. Rombouts, V. Rogiers and A. Geerts. Glutathione levels discriminate between oxidative stress and transforming growth factor-beta signaling in activated rat hepatic stellate cells. J. Biol. Chem. 274: 33881-33887, 1999.
7. Du, G. and J. Zhang. Protective effects of salvianolic acid A against impairment of memory induced by cerebral ischemia-reperfusion in mice. Chin. Med. J. (Engl) 110: 65-68, 1997.
8. Falck-Ytter, Y., Z.M. Younossi, G. Marchesini and A.J. McCullough. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin. Liver Dis. 21: 17-26, 2001.
9. Han, J.Y., J.Y. Fan, Y. Horie, S. Miura, D.H. Cui, H. Ishii, T. Hibi, H. Tsuneki and I. Kimura. Ameliorating effects of compounds derived from Salvia miltiorrhiza root extract on microcirculatory disturbance and target organ injury by ischemia and reperfusion. Pharmacol. Ther. 117: 280-295, 2008.
10. Hu, Y.Y., P. Liu, C. Liu, L.M. Xu, C.H. Liu, D.Y. Zhu and M.F. Huang. Actions of salvianolic acid A on CCl4-poisoned liver injury and fibrosis in rats. Zhongguo Yao Li Xue Bao 18: 478-480, 1997.
11. Kisseleva, T. and D.A. Brenner. Role of hepatic stellate cells in fibrogenesis and the reversal of fibrosis. J. Gastroenterol. Hepatol. 22: Suppl 1, S73-S78, 2007.
12. Kurikawa, N., M. Suga, S. Kuroda, K. Yamada and H. Ishikawa. An angiotensin II type 1 receptor antagonist, olmesartan medoxomil, improves experimental liver fibrosis by suppression of proliferation and collagen synthesis in activated hepatic stellate cells. Br. J. Pharmacol. 139: 1085-1094, 2003.
13. Leonarduzzi, G., A. Scavazza, F. Biasi, E. Chiarpotto, S. Camandola, S. Vogel, R. Dargel and G. Poli. The lipid peroxidation end product 4-hydroxy-2, 3-nonenal up-regulates transforming growth factor beta1 expression in the macrophage lineage: A link between oxidative injury and fibrosclerosis. FASEB J. 11: 851-857, 1997.
14. Li, L.N., R. Tan and W.M. Chen. Salvianolic Acid A, a new depside from roots of Salvia miltiorrhiza. Planta Med. 50: 227-228, 1984.
15. Li, X.J., T. Lei and J.H. Gao. Detection of collagens in hypertrophic scars by picrosirius polarization method. Di Yi Jun Yi Da Xue Xue Bao 22: 217-219, 2002.
16. Li, Z.Z., M. Berk, T.M. McIntyre and A.E. Feldstein. Hepatic lipid partitioning and liver damage in nonalcoholic fatty liver disease: Role of stearoyl-CoA desaturase. J. Biol. Chem. 284: 5637-5644, 2009.
17. Liu, Y.L. and G.T. Liu. Inhibition of human low-density lipoprotein oxidation by salvianolic acid-A. Yao Xue Xue Bao 37: 81-85, 2002.
18. Lu, L.G., M.D. Zeng, J.Q. Li, J. Hua, J.G. Fan, Z.P. Fan and D.K. Qiu. Effect of lipid on proliferation and activation of rat hepatic stellate cells (I). World J. Gastroenterol. 4: 497-499, 1998.
19. Malhi, H., G.J. Gores and J.J. Lemasters. Apoptosis and necrosis in the liver: A tale of two deaths? Hepatology 43: S31-S44, 2006.
20. Mantena, S.K., D.P. Vaughn, K.K. Andringa, H.B. Eccleston, A.L. King, G.A. Abrams, J.E. Doeller, D.W. Kraus, V.M. Darley-Usmar and S.M. Bailey. High fat diet induces dysregulation of hepatic oxygen gradients and mitochondrial function in vivo. Biochem. J. 417: 183-193, 2009.
21. Nair, S., A.M. Diehl, M. Wiseman, G.H. Farr Jr. and R.P. Perrillo. Metformin in the treatment of nonalcoholic steatohepatitis: A pilot open label trial. Aliment. Pharmacol. Ther. 20: 23-28, 2004.
22. Nieto, N., S.L. Friedman and A.I. Cederbaum. Stimulation and proliferation of primary rat hepatic stellate cells by cytochrome P450 2E1-derived reactive oxygen species. Hepatology 35: 62-73, 2002.
23. Nouchi, T., Y. Tanaka, T. Tsukada, C. Sato and F. Marumo. Appearance of alpha-smooth-muscleactin-positive cells in hepatic fibrosis. Liver 11: 100-105, 1991.
24. Pon, L.A. and E.A. Schon (eds.). Methods in Cell Biology Volume. Mitochondria: 2nd edn. Amsterdam: Elsevier Inc., San Diego, 2007, 80: pp. 1-920.
25. Qiang, G.F., L. Zhang, Q. Xuan, X.Y. Yang, L.L. Shi, H.A. Zhang, B.N. Chen and G.H. Du. Effect of metformin on the formation of hepatic fibrosis in type 2 diabetic rats. Yao Xue Xue Bao 45: 801-806, 2010.
26. Qiang, G.F., L. Zhang, X.Y. Yang, Q. Xuan, L.L. Shi, H.A. Zhang, B.N. Chen, X.X. Li, M. Zu, D. Zhou, J. Guo, H.G. Yang and G.H. Du. Effect of valsartan on the pathological progression of hepatic fibrosis in rats with type 2 diabetes. Eur. J. Pharmacol. 685: 156-164, 2012.
27. Sanyal, A.J., P.S. Mofrad, M.J. Contos, C. Sargeant, V.A. Luketic, R.K. Sterling, R.T. Stravitz, M.L. Shiffman, J. Clore and A.S. Mills. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin. Gastroenterol. Hepatol. 2: 1107-1115, 2004.
28. Sanyal, A.J., N. Chalasani, K.V. Kowdley, A. McCullough, A.M. Diehl, N.M. Bass, B.A. Neuschwander-Tetri, J.E. Lavine, J. Tonascia, A. Unalp, M. Van Natta, J. Clark, E.M. Brunt, D.E. Kleiner, J.H. Hoofnagle, P.R. Robuck and NASH CRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N. Engl. J. Med. 362: 1675-1685, 2010.
29. Serviddio, G., F. Bellanti, J. Sastre, G. Vendemiale and E. Altomare. Targeting mitochondria: A new promising approach for the treatment of liver diseases. Curr. Med. Chem. 17: 2325-2337, 2010.
30. Silverman, J.F., W.J. Pories and J.F. Caro. Liver pathology in diabetes mellitus and morbid obesity. Clinical, pathological, and biochemical considerations. Pathol. Annu. 24 Pt 1: 275-302, 1989.
31. Sugimoto, R., M. Enjoji, M. Kohjima, S. Tsuruta, M. Fukushima, M. Iwao, T. Sonta, K. Kotoh, T. Inoguchi and M. Nakamuta. High glucose stimulates hepatic stellate cells to proliferate and to produce collagen through free radical production and activation of mitogen-activated protein kinase. Liver Int. 25: 1018-1026, 2005.
32. Tolman, K.G., V. Fonseca, M.H. Tan and A. Dalpiaz. Narrative review: Hepatobiliary disease in type 2 diabetes mellitus. Ann. Intern. Med. 141: 946-956, 2004.
33. Tsai, M.K., Y.L. Lin and Y.T. Huang. Effects of salvianolic acids on oxidative stress and hepatic fibrosis in rats. Toxicol. Appl. Pharmacol. 242: 155-164, 2010.
34. Wen, X.D., C.Z. Wang, C. Yu, Z. Zhang, T. Calway, Y. Wang, P. Li and C.S. Yuan. Salvia miltiorrhiza (dan shen) significantly ameliorates colon inflammation in dextran sulfate sodium induced colitis. Am. J. Chin. Med. 41: 1097-1108, 2013.
35. Yang, X.Y., L. Sun, P. Xu, L.L. Gong, G.F. Qiang, L. Zhang and G.H. Du. Effects of salvianolic acid A on plantar microcirculation and peripheral nerve function in diabetic rats. Eur. J. Pharmacol. 665: 40-46, 2011.
36. Zhang, Y.Q., Y. Tang, A.L. Wu and H.B. Zhu. Salvianolic acid A displays cardioprotective effects in in vitro models of heart hypoxia/reoxygenation injury. J. Asian Nat. Prod. Res. 12: 899-915, 2010.